The company received a positive regulatory opinion from the EMA CHMP for mavorixafor in WHIM syndrome, representing a significant milestone toward EU market approval. This is expected to expand the company's commercial footprint beyond the U.S., with a lucrative partnership agreement with Norgine providing up to €226 million in milestone payments and double-digit royalties. The drug would be the first and only therapy in Europe for this indication.
Also mentions XFOR
Articles that tag XFOR but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
